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Background: Rectal cancer accounts for approximately one third of all colorectal cancers (CRC), which belong
among leading causes of cancer deaths worldwide. Standard treatment for locally advanced rectal cancer (cT3/4
and/or cN+) includes neoadjuvant chemoradiotherapy with fluoropyrimidines (capecitabine or 5-fluorouracil)
followed by radical surgical resection. Unfortunately, a significant proportion of tumors do not respond enough to
the neoadjuvant treatment and these patients are at risk of relapse. MicroRNAs (miRNAs) are small non-coding
RNAs playing significant roles in the pathogenesis of many cancers including rectal cancer. MiRNAs could present
the new predictive biomarkers for rectal cancer patients.
Methods: We selected 20 patients who underwent neoadjuvant chemoradiotherapy for advanced rectal cancer
and whose tumors were classified as most sensitive or resistant to the treatment. These two groups were
compared using large-scale miRNA expression profiling.
Results: Expression levels of 8 miRNAs significantly differed between two groups. MiR-215, miR-190b and
miR-29b-2* have been overexpressed in non-responders, and let-7e, miR-196b, miR-450a, miR-450b-5p and
miR-99a* have shown higher expression levels in responders. Using these miRNAs 9 of 10 responders and 9 of
10 non-responders (p < 0.05) have been correctly classified.
Conclusions: Our pilot study suggests that miRNAs are part of the mechanisms that are involved in response of
rectal cancer to the chemoradiotherapy and that miRNAs may be promising predictive biomarkers for such patients.
In most miRNAs we identified (miR-215, miR-99a*, miR-196b, miR-450b-5p and let-7e), the connection between
their expression and radioresistance or chemoresistance to inhibitors of thymidylate synthetase was already
established.
Keywords: Rectal cancer, microRNA, Prediction, Neoadjuvant chemoradiotherapy, Radiation, Capecitabine,
5-fluorouracil, Thymidylate synthetaseIntroduction
Carcinomas of the colon and rectum (colorectal cancer,
CRC) are among leading causes of cancer-related deaths
worldwide and in Czech Republic, the incidence of CRC is
one of the highest in the world [1,2]. Cancer of the rectum
and rectosigmoideal junction (hereinafter referred to as* Correspondence: msvoboda@mou.cz
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reproduction in any medium, provided the or“rectal tumors”) make up 30% to 40% of all CRC [3,4] and
adenocarcinomas represent the absolute majority of them
[4]. About 45% of rectal tumors is diagnosed as locally
advanced rectal adenocarcinoma (LARA) in Czech Re-
public [3]. According to TNM classification, these are
tumors in clinical stage II. and III., defined as cT3 or cT4,
and/or tumors in which the regional lymphatic nodes are
affected (cN1 or cN2) [5]. Compared to colon tumors,
LARA are more likely, after surgical treatment, to relapse
locally, metastasize to lungs and often lead to a serious de-
cline in quality of patient’s life [6-8]. To achieve a betteral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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probability of a radical surgery with preservation of the
anal sphincter and avoidance of a permanent colostomy,
LARA treatment is based most often on application of
neoadjuvant chemoradiotherapy with fluoropyrimidines
followed by surgical treatment and, eventually, adjuvant
chemotherapy [9-13].
The neoadjuvant chemoradiotherapy brings a signifi-
cant regression in more than 2/3 of tumors (TRG1,
TRG2, and most of tumors evaluated as TRG3 according
to Mandard’s classification; TRG – tumor regression
grade) and in approximately 15 – 20% of patients the
complete eradication of tumor is achieved [11-13], called
a pathological complete response (pCR; ypT0 in TNM
classification, TRG1 in Mandard’s classification) [14].
Several retrospective analyses suggest that the tumor
stage after neoadjuvant treatment has a significant prog-
nostic impact on a disease-free (DFS) and overall sur-
vival (OS) [11-13]. There is, nevertheless, a significant
subgroup of rectal cancer patients (approx. 20%) having
poor response to the neoadjuvant therapy (TRG5, TRG4
and a part of TRG3 classified tumors) [14-16]. There-
fore, the ability to predict response for neoadjuvant che-
moradiotherapy may allow individualization and more
rational selection of patients that will most likely benefit
from this therapy.
MicroRNAs (miRNAs) are highly conserved, small,
non-coding RNAs, 18–25 nucleotides in length, that act
as post-transcriptional regulators of gene expression by
silencing their mRNA targets. Recent studies showed
that miRNAs regulate a significant number of onco-
genes, tumor suppressor genes, and genes associated
with the invasion, dissemination, and therapy resistance
of many tumors [17]. In colorectal cancer, polymorph-
isms within miRNAs binding regions have been
described as new risk factors. Several genome-wide pro-
filing studies have identified miRNAs deregulated in
CRC tissue. A number of experimental studies on these
miRNAs revealed insight into miRNA-mediated regula-
tory links to well-known oncogenic and tumor suppres-
sor signaling pathways [17]. Several investigations have
also described the ability of specific miRNA expression
profiles to predict prognosis and therapy response in
CRC patients [17-19].
The aim of this study was to analyse global miRNA ex-
pression profiles in the clinical samples of rectal tumors
to identify miRNA signatures specific for responders and
non-responders to neoadjuvant chemoradiotherapy in
patients with LARA.
Material and methods
Patients
This retrospective study included 20 patients with previ-
ously untreated and histologically confirmed locallyadvanced rectal adenocarcinoma (LARA). All patients
underwent neoadjuvant chemoradiotherapy based on
concurrent application of radiotherapy (45 Gy to pelvis
plus 5.6 Gy boost to tumor; 1,8 Gy/day, 5 days/week
with all fields being treated daily) and chemotherapy
(capecitabine 825 mg/m2, per os, twice a day daily, or
5-fluorouracil as a continuous i.v. infusion at a daily
dose 225 mg/m2, both drugs were administered
throughout the radiotherapy) which was followed by sur-
gical treatment of the tumor and, eventually, adjuvant
chemotherapy by the same cytostatic that was used in
neoadjuvant therapy. The dose of radiotherapy or
chemotherapy was not reduced in any of the patients.
Surgery was scheduled 6 weeks after completion of che-
moradiotherapy. Techniques of surgery were standar-
dized and we are basically looking at three types of
surgery (APR – abdominoperineal resection, LAR – low
anterior resection, uLAR – ultra low anterior resection);
TME (total mesorectal excision) was always performed.
The response of the tumor to neoadjuvant therapy was
evaluated in several ways. TNM classification was used
for clinical purposes (5). For our project, evaluation
of tumor regression was done in two ways: 1. using a
grading system adapted from Mandard et al. (14), and
2. establishing an average and a maximal percentual rep-
resentation of residual cancer cells in the cell population
detected in 10 examined slices of formalin fixed and par-
affin embedded primary tumors. Of these 20 patients, 10
patients responded and 10 patients did not respond to
the neoadjuvant chemoradiotherapy. Patients that
responded to the therapy (the “responders”) were those
whose tumor regression after the therapy reached the
classification TRG1 or TRG2. In tumors classified as
TRG2, the average of residual tumor cells could not ex-
ceed 10% of the entire cell population detected in the
examined slices and/or 50% in at least one of the exam-
ined slices. Patients that did not respond to the therapy
(the “non-responders”) were those whose tumors
showed after the neoadjuvant therapy no regression
(TRG5) or just partial regression in cancer cell popula-
tion (TRG4 and TRG3). Tumors evaluated as TRG3
were marked as non-responders only when maximal
number of residual cancer cells reached 50% in at least
one of the examined slices. Informed consent was
obtained from all patients, and the local Ethical Board
approved the study protocol. Detailed characteristic of
patients and their tumors is summarized in Table 1.
Tissue sample preparation and miRNA isolation
Bioptic samples of untreated primary tumors were im-
mediately stored in liquid nitrogen until RNA extraction.
All analyzed tissues were homogenized (Retsch MM301)
and total RNA enriched for small RNAs was isolated
using mirVana miRNA Isolation Kit (Ambion, USA).
Table 1 Patient characteristics
Patient Gender Age Clinical
stage
AC
[cm]
Chemotherapy CEA CA
19-9
Type of
surgery
Histology Grade L/V/P cT cN ypT ypN TRG Residual cancer
cells Avg/Max %
Local
relaps
Distant
relaps
Responders 01 M 30 IIIA 12 Xel N N LAR A 1 0 1 1 1 0 2 1/5 0 0
02 F 62 IIIA 13 Xel N N LAR A 2 0 x 1 1 1 2 2,5/5 0 0
03 F 67 IIA 3,5 Xel N N APR A 2 0 3 0 1 0 2 7,5/15 0 0
04 M 43 IIIA 9 Xel N N uLAR A 1 0 2 1 0 0 1 0/0 0 0
05 M 40 IIIB 5 Xel E N APR A 2 0 3 1 3 1 2 1/5 0 0
06 M 73 IIA 6,5 Xel N E uLAR A 2 0 3 0 0 0 1 0/0 0 0
07 M 68 IIIC 6 Xel E E APR A 2 0 3 2 0 0 1 0/0 0 0
08 M 58 IIIB 13 Xel N N APR A 1 0 3 1 3 0 2 2,5/40 0 Y
09 M 68 IIA 4,5 5FU N N APR A 2 0 3 0 0 0 1 0/0 0 0
10 M 43 IIA 4 Xel N N uLAR MA 2 0 3 0 0 0 1 0/0 0 0
Non-responders 11 M 63 IIIB 7 Xel E N uLAR A 2 0 3 1 2 0 4 15/50 0 0
12 M 59 IIIB 9 Xel E N LAR A 2 0 3 1 3 0 4 40/60 0 0
13 M 45 IIIC 4 Xel N N APR A 2 1P 3 2 3 1 3 7,5/50 Y Y
14 F 64 IIIC 11 Xel N N LAR A 2 0 3 2 2 0 4 50/70 0 0
15 F 60 IIIA 9 Xel N N LAR A 1 0 2 1 1 0 4 70/80 0 0
16 F 69 IIIC 8 Xel N N LAR A 1 0 3 2 3 1 4 25/70 0 0
17 M 32 IIIC 10 Xel N N LAR A 2 0 2 2 3 0 4 55/75 0 0
18 M 53 IIIC 4 Xel N N APR A 3 0 3 2 2 0 3 40/60 0 0
19 M 63 IV* 7 5FU E N APR MA 2 0 3 2 3 2 4 60/80 0 Y
20 F 52 IIA 8 Xel N N LAR A 2 0 3 0 2 1 3 60/70 0 0
N – Normal; E – Elevated; LAR – Low Anterior Resection; uLAR – Ultra (extended) Low Anterior Resection; APR –Abdominoperineal Resection; A – Adenocarcinoma; MA – Mucinous Adenocarcinoma; L/V/P – Lymphatic/
Vascular/Perineural Invasion; 1P – Positive Perineural Invasion; TRG – Tumor Regression Score according to Mandard et al. (10); CEA – Carcinoembryonic antigen; CA 19–9 – cancer antigen 19–9; Clinical stage –
according to TNM /UICC cancer staging classification, 6th Edition (ref. 5); cT/cN – clinical staging of primary tumor (T) / regional lymphatic nodes (N); ypT/ypN – histopathological staging of primary tumor and regional
lymphatic nodes after neoadjuvant treatment; Residual cancer cells (Avg/Max %) – a proportion of cancer cells in all paraffin embedded tisue slices of primary tumor histologicaly examined after neoadjuvant
treatment: Average (%) / Maximum (%) of cancer cells presented in examined slices; Xel – Xeloda (capecitabine); 5FU – 5-fluorouracil; M – male; F – female; AC – distance between the anocutaneous line and distal
(aboral) margin of the tumor in cm; Y – yes; * in such patient a radical metastasectomy of solitary liver metastasis was first performed, followed by neoadjuvantchemoradiotherapy for locally advanced rectal cancer.
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by UV spectrophotometry (A260/A280 > 2.0; A260/
A230 > 1.8) using Nanodrop ND-1000 (Thermo Fisher
Scientific, USA).
Large-scale miRNA expression profiling
We performed TaqMan Low Density Arrays (TLDA)
analysis to identify profile of differentially expressed
miRNAs between the two sets of biopsy samples
(10 responders and 10 non-responders to neoadjuvant
chemoradiotherapy for rectal cancer). In brief, 350 ng of
total RNA was reverse-transcribed into cDNA by the
TaqMan MicroRNA Reverse Transcription Kit and
Megaplex RT set pool A and B version 2.0 (Applied Bio-
systems, USA). The RT product was loaded into Taq-
Man Array Human MicroRNA A+B Cards Set v2.0
(Applied Biosystems, USA) enabling simultaneous quan-
titation of 667 human miRNAs. TaqMan MicroRNA
Assays and analysis were performed on the ABI 7900HT
Instrument (Applied Biosystems, USA). All reactions
were performed according to the standard manufac-
turers’ protocols. Quantitative miRNAs expression data
were acquired and normalized by use of ABI 7900HT
SDS software (Applied Biosystems, USA).
Statistical methods
The obtained primary data were analysed using the
SDS 2.0.1 software and RQ Manager 1.2 (Applied
Biosystems, USA) (settings: automatic baseline, thres-
hold 0.2). RNU48 has been used as reference gene for
normalization of miRNAs expression levels. The rela-
tive expression levels of target miRNAs were deter-
mined by the equation 2−ΔCT, in which ΔCT were
calculated as follows: ΔCT = CT miR-of-interest − CT
RNU48. Normalized expression data were statistically
evaluated in the environment of statistical language R
by use of Bioconductor package and LIMMA approach
combined with hierarchical clustering (HCL) [20]. Pu-
tative miRNAs’ targets were predicted using miRWalk
database and miRanda algorithm [21].
Results
To determine whether the miRNA expression profiles
differ between responders and non-responders to the
neoadjuvant chemoradiotherapy in rectal cancer
patients, large-scale miRNA expression analysis was per-
formed on 20 samples of preoperative biopsies of rectal
cancer tissues (see Table 1 for Patients characteristics).
Through LIMMA approach 8 miRNAs indicating signifi-
cantly different expression levels between both groups
were identified (see Table 2). Of these, miR-215, miR-
190b and miR-29b-2 have been overexpressed, and let-
7e, miR-196b, miR-450a, miR-450b-5p and miR-99a have
shown lower expression levels in non-responders. Usingthese miRNAs, we were able to correctly classify 9 of 10
(90%) responders and 9 of 10 (90%) non-responders
(p < 0.05). The results are graphically presented as hier-
archical clustergram in Figure 1.Discussion
Approximately 20% of LARA’s are primary resistant
tumors in which there is no reduction or just minimal
reduction in the number of cancer cells after neoadju-
vant therapy based on concurrent application of radi-
ation and chemotherapy with fluoropyrimidines [14-16].
Should there be valid predictive factors, these patients
would be spared exposure to chemotherapy and radi-
ation associated with substantial adverse effects and
costs and surgery could be scheduled without delay.
MiRNAs constitute a robust regulatory network with
post-transcription regulatory efficiency for almost one
half of human coding genes, including important onco-
genes, tumor suppressor genes, and genes associated
with the invasion, dissemination, and therapy resistance
of many tumors [17]. We have used a large-scale miRNA
expression profiling and identified 8-miRNAs signature
(miR-215, let-7e, miR-196b, miR-190b, miR-29b-2*, miR-
450a, miR-450b-5p and miR-99a*) enabling correct classi-
fication of 90% of responders (9/10) and non-responders
(9/10) to neoadjuvant chemoradiotherapy in patients with
LARA. In 5 (miR-215, miR-99a*, miR-196b, miR-450b-5p
and let-7e) out of 8 identified miRNAs a potential linkage
was already established between their expression and
radioresistance or chemoresistance to thymidylate synthe-
tase (TS) inhibitors.
The most frequently studied and the most promising
miRNA identified in our study is miR-215, because
current knowledge partly enables mechanistical explan-
ation of its association with chemoradioresistance. Song
et al. provides direct evidence that miR-215 regulates the
TS mRNA in HCT116 colon cancer cell line. Ectopic ex-
pression of miR-215 decreased the expression of TS
mRNA and protein and at the same time miR-215 inhi-
bits cell proliferation and increased chemoresistance to
TS inhibitor raltitrexed. Inhibition of cell proliferation
and subsequent chemoresistance was caused by the
induction of G2-arrest [22]. Similar results were pub-
lished by Boni et al., who used in their experiments
5-fluorouracil [23]. Cell cycle arrest as a result of
increased expression of miR-215 was confirmed on
model of colorectal cancer also by another independent
study [24] and our previous results [25]. A further and
very important discovery was the fact that miR-215 reg-
ulates the cell cycle not only in colon cancer cells but
also in colon cancer stem cells. Recent data suggest that
colon cancer stem cells may utilize miR-215 to slow cell
proliferation and avoid damage caused by chemotherapy
Table 2 Overview of miRNAs with significantly different levels of expression in rectal tumors of responders and
non-responders to neoadjuvant chemoradiotherapy
MiRNAs R NR Fold change (NR vs R) P-value Putative targets†#
miR-450b-5p U D 0.07 0.0003 RANBP9, SLC19A2, XIAP, RGMB, SMAD2, SERPINA5, SOX2, TCF5, TIMP2, TGFBR2
let-7e U D 0.48 0.0075 NRAS#, KRAS#, SOCS1#, HMGA2#, ABCC5, HOXD1, MASP1, ERCC6, IGF1
miR-450a U D 0.16 0,0104 MAP3K2, RAB31, TOPBP1, CREB1, DNMT3A, EGFR, ERCC5
miR-99a* U D 0,21 0,0163 RAD51C, RAD9B, TIAM1, TMEM87a, TMEM71, SOCS4, RANBP4, RANBP6
miR-190b D U 4.03 0.0290 CDKN1B, MUC17, MYCBP2, SMAD2, TCF4, CASP2, TP53INP1
miR-29b-2* D U 4.25 0.0375 AKT3, RANBP9, PARP2, HDAC5, CDKN3, AGR2, SLC19A2, FOXN3
miR-215 D U 4.40 0.040 ZEB2#, ALCAM#, TYMS (TS) #, DHFR#, EREG, HOXB9, NOD2
miR-196b U D 0.42 0,043 HOXB8#, HOXC8#, ERG#, BACH1#, FAS, TBRG1, TOX3
Legend: R – responders, NR – non-responders, D – down-regulated expression, U – up-regulated expression. # Target is experimentally validated. † Putative targets
were predicted using miRWalk database and miRanda algorith (21) and subsequently selected on the basis of their significance in tumor biology, particularly in
the processes of cell survival and resistance to anti-cancer treatment.
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ferentiation signal [22].
Observations on in vitro models were confirmed in
clinical practice as well. Karaayvaz et al. showed that
high levels of miR-215 expression in cancer tissues are
closely associated with poor overall survival of patients
with colon cancer in stage II and III (HR 3.516; P=0.025)
[26]. These results are in agreement with our results
showing down-regulation of miR-215 in LARA respond-
ing to chemoradiotherapy.Figure 1 Hierarchical clustering of 10 responders and 10
non-responders to neoadjuvant chemoradiotherapy stratified
according to the expression profile of 8 miRNAs differentially
expressed between these two groups. Yellow color indicate
samples of non-responders, blue responders to neoadjuvant therapy,
p<0.05.The let-7 family of miRNAs (let-7a through let-7h)
regulates expression of key oncogenes, such as RAS and
MYC, and is specifically down-regulated in many cancer
types. Weidhaas et al., reported that the let-7 family is
over-represented in a class of miRNAs exhibiting altered
expression in response to radiation. Using C. elegans–
based in vivo model of radiation-induced reproductive
cell death, they confirm the ability of let-7 family of miR-
NAs to increase radiosensitivity when over-expresed
[27]. Accordingly, we have observed up-regulation of let-
7e in tumors of therapy responders.
Another predictive miRNA identified in our study,
miR-99a*, was previously observed in work of Bandres
et al. as up-regulated in tumors of responders to neoad-
juvant chemoradiotherapy [28]. Interestingly, among
putative targets of miR-99a* are important proteins
involved in DNA repair – RAD51C and RAD9B [29].
Up-regulation of miR-99a* in tumors could be associated
with lower DNA repair capacity through down-regulation
of these genes, which may lead to radiotherapy
sensitization. One of the putative targets of miR-450b-5p,
another up-regulated miRNA in tumors of patients
responding to therapy, is a gene coding the X-linked inhibi-
tor of apoptosis protein (XIAP). It was shown that knock-
down of XIAP in vitro lead to sensitization of colon cancer
cells to irradiation [30]. In case of miR-196b, our research
group published a study in which we established that ele-
vated expression of miR-196b was positively correlated with
overall survival (HR 0.5470; P = 0.0492) in glioblastoma
patients treated with concomitant chemoradiotherapy [31].
Till now, there are only two studies that analyzed glo-
bal miRNA expression profiles in LARA to find potential
predictive miRNAs for response to neoadjuvant chemor-
adiotherapy. The first study was performed by Scarpati
et al. [18]. They have found 14 miRNAs (miR-1183,
miR-483-5p, miR-622, miR-125a-3p, miR-1224-5p, miR-
188e5p, miR-1471, miR-671-5p, miR-1909, miR-630,
miR-765, miR-1274b, miR-720, hsv1-miR-H1) differen-
tially expressed between group of tumors in which, after
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occured (TRG1/pCR) vs. control group that contained
all other tumors (TRG2, TRG3, TRG4). There is no
overlap between miRNA signature identified in this
study and our results. We suppose that the cause of this
discrepancy is in a different and, in part, also unsuitable
design of Scarpati’s study, as 55% of tumors in control
group reached expressive regression of cancer cells clas-
sified by TRG2 grade. This evaluation practically means
that there was almost complete remission of tumor cells.
Moreover, patients in their study received only dose of
45 Gy and as chemotherapy oxaliplatine was used. From
biological point of view, it can be expected that tumors
in which total or almost total regression was achieved
after neoadjuvant chemoradiation therapy, would share
same or similar gene profiles and protein expression. It
can also be expected that if tumors in Scarpati study
were given radiation dose of 50 Gy, most of the tumors
in group TRG2 would reach total eradication of tumor
cells (TRG1/pCR).
Second study was published in the form of an ab-
stract by Bandres et al. on ASCO 2012 Annual Meet-
ing (28). Bandres’ and our studies are much more
similar since we used the same therapy procedures for
patients with LARA and we also used similar designs
for the study. Bandres et al. identified a miRNA signa-
ture that correctly differentiated extreme-phenotype of
responders (TRG1) and non-responders (TRG4). They
found up-regulation of miR-21*, miR-99*, miR-125b,
miR-125b1*, let-7c and miR-490 to be significantly cor-
related with a higher likelihood of achieving TRG1/
TRG2 response, and down-regulation of miR-21* and
miR-125a-3p to be associated with a TRG-4 response.
Our results are in agreement at least in case of miR-
99* and let-7 family. As far as the rest of miRNAs is
concerned, only in case of miR-21* our data showed a
difference between group of responders and non-
reponders indicating trend but have not reached statis-
tical significance (p=0,11).Conclusion
Taken together, our results support hypothesis that
miRNAs are part of the mechanisms that are involved
in response of rectal cancer to the chemoradiotherapy
and that miRNA’s could be promising predictive bio-
markers for patients undergoing such treatment. In
most of miRNA’s we identified (miR-215, miR-99a*,
miR-196b, miR-450b-5p and let-7e), the potential link-
age between their expression and radioresistance or
chemoresistance to inhibitors of thymidylate synthetase
was already established, but some of them were identi-
fied for the first time. Therefore, the mechanisms and
predictions obtained in this study need to be furthervalidated in more detailed models and on an independent
set of patients, before applying in clinical practice.
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